A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Cobimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Gastric cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 032
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Oct 2017 Results presented in a Bristol-Myers Squibb Media Release.
    • 16 Oct 2017 According to a Bristol-Myers Squibb media release, data will be presented at the 18th World Conference on Lung Cancer (WCLC).
    • 12 Sep 2017 Results (n=25) of an exploratory subgroup analysis evaluating objective response rate and overall survival by microsatellite instability (MSI) status in patients with esophagogastric cancer treated with Nivolumab monotherapy in CheckMate 032 study, presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top